Allogene Therapeutics, Inc.

NASDAQ:ALLO

3.08 (USD) • At close November 8, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2023202220212020201920182017
Operating Activities:
Net Income -327.265-332.632-257.005-250.221-184.594-211.505-0.024
Depreciation & Amortization 14.19914.29510.4547.5865.0271.50
Deferred Income Tax 7.5028.07910.3994.404-0.331-0.1170
Stock Based Compensation 65.95183.680.81865.26146.06318.5660
Change In Working Capital -15.3053.706-32.08953.922-6.87812.0960.024
Accounts Receivables 0000000
Inventory 0000000
Accounts Payables -7.5024.868-0.7670.615-0.9858.80
Other Working Capital -7.803-1.162-31.32253.307-5.8933.2960.024
Other Non Cash Items 17.1852.4332.6113.9553.363134.8070
Operating Cash Flow -237.733-220.519-184.812-115.093-137.35-44.6530
Investing Activities:
Investments In Property Plant And Equipment -1.516-5.191-21.446-65.958-50.791-3.2340
Acquisitions Net -164.805-111.35-17.71439.165-5.07500
Purchases Of Investments -438.629-248.109-525.583-1,037.591-252.628-649.3070
Sales Maturities Of Investments 603.434359.459728.394598.426472.57821.8410
Other Investing Activites 164.805111.35185.101-439.165214.875-2.0980
Investing Cash Flow 163.289106.159163.655-505.123164.084-632.7980
Financing Activities:
Debt Repayment 00000-116.8420
Common Stock Issued 91.1122.9511.963621.93358.96654.340
Common Stock Repurchased 2.4962.4613.6172.8431.78300
Dividends Paid 0000000
Other Financing Activities 95.6952.9511.9638.81558.96771.1820
Financing Cash Flow 95.6952.9511.963633.59158.96771.1820
Other Information:
Effect Of Forex Changes On Cash 0000000
Net Change In Cash 21.251-111.41-9.19413.37585.69493.7310
Cash At End Of Period 93.44772.196183.606192.8179.42593.7310